FSD Pharma Inc., Developing its PEA Compound to Treat COVID-19, CEO Clip Video

Stock Information for FSD Pharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About FSD Pharma Inc.

FSD Pharma Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia
FSD Pharma Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd(TM) in an Induced State of Alcohol Intoxication
FSD Pharma Provides Update from Celly Nu's Partnership with Six+One for unbuzzd(TM)
FSD Pharma Provides Another Update on Celly Nu's Anticipated Launch of unbuzzd(TM)
FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption
FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
FSD Pharma Announces Filing of Year-End 2023 Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.